http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2013267034-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_034bfd56a60f64c13aedf7b0e71dead6 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-06 |
| filingDate | 2013-12-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_61a11f267f50514f8e0c95cc3631ccdb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6dcc1a844bdb7ebe30a07f47aa2038be http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6a5495ce042947565a288dc11303f41a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cad403b1287549d935231a1edeb91c9f |
| publicationDate | 2014-01-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AU-2013267034-A1 |
| titleOfInvention | Compounds for enzyme inhibition |
| abstract | COMPOUNDS FOR ENZYME INHIBITION Peptide-based compounds including heteroatom-containing, three-membered 5 rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases associated with the proteasome. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti inflammatory properties and inhibition of cell proliferation. Oral administration of 10 these peptide-based proteasome inhibitors is possible due to their bioavailability profiles. |
| priorityDate | 2005-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 810.